We’ve teamed up with the Colorectal Cancer Alliance to help advance colorectal cancer research. The Genetic Insights into Colorectal Cancer in the Black Community study is part of 23andMe’s continued efforts to raise awareness about important health conditions that touch many individuals but disproportionately impact the Black and African American communities. Eligible participants will receive the 23andMe Health + Ancestry Service and compensation for their time and effort in helping us with this research. Learn more here: https://23and.me/4bNxw5i
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
Get directions
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
Get directions
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
Congratulations to our very own Maya Lowe for being featured in the San Francisco Business Times for "The Business of Pride" series! 🧬🌈 https://lnkd.in/gEUGiZuq
-
Research on Parkinson's disease by scientists at 23andMe, with support from The Michael J. Fox Foundation for Parkinson's Research, has uncovered new insights into the natural history of the LRRK2 G2019S variant. The findings, tracing back thousands of years, vividly illustrate how our DNA braids together history, ancestry, and health. Read more: https://23and.me/3X8IIVK #ParkinsonsDisease #Genetics
The Natural History of a Genetic Variant Associated with Parkinson's Disease
blog.23andme.com
-
This week, we released a new Bipolar Disorder PRS report*, adding to a collection of genetic reports focused on mental health that are available for 23andMe+ Premium members. Bipolar disorder affects millions of people worldwide, and according to the National Institute of Mental Health, an estimated 4.4 percent of American adults will experience bipolar disorder at some time in their lives. While research to fully understand the causes of bipolar disorder is ongoing, there are effective treatments, as well as strategies for managing the symptoms. Learn more: https://23and.me/3Xa71CB *The 23andMe Bipolar PRS report is based on a genetic model that includes data and insights from 23andMe consented research participants and incorporates thousands of genetic variants to provide information on the likelihood of developing bipolar disorder. The report does not describe a person’s overall likelihood, does not account for lifestyle or family history and has not been reviewed by the FDA. The Bipolar PRS report is not intended to tell you anything about your current state of health, or to be used to make medical decisions or determine any treatment.
-
-
Recapping an exciting week for 23andMe - our first ASCO! At the 2024 American Society of Clinical Oncology (ASCO) annual conference, we presented positive Phase 2 data from the Phase 1/2a clinical trial of 23ME-00610, our first wholly-owned antibody to enter the clinic. The 23andMe Therapeutics team presented the first data on monotherapy efficacy, including evidence of preliminary clinical benefit, and emerging biomarker data for 23ME-00610. Read more here: https://23and.me/4e8dnbK
-
-
We’re excited to announce that we’ve teamed up with the Colorectal Cancer Alliance to raise awareness about colorectal cancer risk and help advance colorectal cancer research in the Black and African American community. Learn more here: https://23and.me/3X88g5m
-
-
23andMe reposted this
Health is wealth with Dr. Noura Abul-Husn at 23andMe! During her speech at the 2024 #MAKERSConference, she redefines healthcare from being reactive to proactive. With insightful exercises and examples, we learn more about health, prevention, and the power of genetics. Here's to taking charge of our health and ownership of our future! 💪🧬 #HealthEmpowerment #ProactiveHealthcare #SelfCare #GeneticInsights #MAKERSWomen #Wellness #WomensHealth
-
Meet the 23andMe Therapeutics team at #ASCO24 next week! We look forward to sharing preliminary efficacy and biomarker data for our lead investigational, first-in-class antibody 23ME-00610 in the treatment of multiple advanced solid tumors. https://lnkd.in/gY5ECQ6R #ASCO24
-
-
Dr. Noura Abul-Husn, our VP of Genomic Health, spoke last week at The National Institutes of Health / National Human Genome Research Institute (NHGRI), continuing to advance the conversation of genetics and healthcare.
Vice President @ 23andMe | Physician Scientist and Executive | Genomic Medicine and Personalized Health
Such an honor to visit and speak at The National Institutes of Health / National Human Genome Research Institute (NHGRI) today! 🧬🩺 Thanks to all for the warm welcome and engaging discussions, and a special thanks to my host Dr. Neil Hanchard and the wonderful trainees I got to spend time with.
-
-
23andMe reposted this
New update from Lemonaid Health! We’re now offering Stendra®, a FDA-approved medication for treating erectile dysfunction – proven to be effective in ~15 minutes. Start your online visit today to determine if treatment is right for you. If prescribed, you can have Stendra® delivered discreetly with free shipping. Learn more: https://bit.ly/4bnUnEw *Individual results may vary. Medication only available if prescribed. Prescription products require completion of an independent medical consultation through Lemonaid Health platform. Additional terms and conditions also apply. See lemonaidhealth.com to learn more. Services and products available in all 50 states and the District of Columbia, subject to local laws.
-